Navigation Links
Randomized Study Comparing Cell Therapeutics' OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
Date:8/18/2011

leasing the paclitaxel chemotherapy.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.

Sign up for email alerts and get RSS feeds at CTI's Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of OPAXIO include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with OPAXIO in particular, including, without limitation, the potential failure of OPAXIO to prove safe and effective and/or less toxic and effective for the treatment of newly diagnosed high-grade malignant brain tumors such as GBM, including when combined with TMZ and RT, the potential failure of OPAXIO when combined with TMZ and RT to provide PFS and OS responses to newly-diagnosed high-grade malignant brain tumors such as GBM, that the results of the new OPAXIO study may not be positive or be used to plan a phase III study of OPAXIO for approval for use in treating newly diagnosed GBM, that CTI cannot predict or guarantee the pace of patient enrollment in the phase II clinical study comparing OPAXIO to TMZ, Brown  and CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling CTI's product candidates such as OPAXIO, and the risk factors listed or described from tim
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
2. Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone
3. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
4. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
5. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
6. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
7. Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans
8. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
9. Harvest Technologies Announces Completion of Patient Enrollment in its Randomized, Controlled, Double Blind Multicenter IDE Non-Reconstructable Critical Limb Ischemia Trial
10. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
11. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 17, 2015  Centrillion Technologies, a genomic ... from the National Human Genome Research Institute, ... (NIH). The grant will help fund the ... of breakthrough genomic technologies, including phased sequencing ... Centrillion has been developing this transformative and ...
(Date:4/17/2015)... 2015 CIO Review ( http://www.cioreview.com ) ... Most Promising Pharma and Life Science Technology Solution Providers ... compliance software platform for life sciences companies. , ... panel of experts and members of CIO Review’s editorial ... Platform has been on our radar for some time ...
(Date:4/17/2015)... 2015  Guggenheim Securities, the investment banking and capital ... of William Tanner as a Managing Director ... will start work at Guggenheim in May 2015 in ... "Bill brings a wealth of biotech experience, ... and highly acclaimed healthcare team," said Matthew Johnson ...
(Date:4/17/2015)... Global Stem Cells Group has ... 2015 April 27 - 29, 2015 in Boston. This ... areas of stem cell research including applications, biology, medicine, ... medicine. , The conference will address recent developments ... research in stem cell therapies, regenerative medicine, tissue engineering, ...
Breaking Biology Technology:MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3
... 3 Caliper Life,Sciences, Inc. (Nasdaq: CALP ... 26th Annual Healthcare Conference will be webcast on ... Hrusovsky, President and CEO of,Caliper, will be providing ... can be accessed at, http://www.metameetings.com/webcasts/jpmorgan/healthcare08/ . An archived,presentation ...
... MEDX ) announced today that it is scheduled ... 10:30 a.m. ET on Tuesday, January,8, 2008. The event ... the,Investor Relations section of the Medarex Web site at ... be available following the event., About Medarex, ...
... Mass., Jan. 3 Mersana, a cancer therapeutics,company, ... as Chairman of,the Company,s Board of Directors. Mr. ... a significant record of accomplishment over a,30-year industry ... welcome Boyd Clarke as Chairman of our Board,of ...
Cached Biology Technology:Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors 2
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... University biologist has been awarded over $2.3 million from ... of the human pathogen chlamydia in hopes of finding ... disease in the United States. David E. Nelson, ... Arts and Sciences, Department of Biology, and researchers in ...
... invading virus hijacks a cell,s workings by imitating a ... cell signals, the virus destroys a defensive protein designed ... cell cultures, may represent a broader targeting strategy used ... for developing more effective treatments for infectious diseases. ...
... buzz of the golden-winged warbler,s song might not sound like ... population of this little, gray songbird with bright yellow patches ... since 1966. And, as of yet, it remains unprotected by ... dire situation for the warbler, and Ronald Canterbury wants people ...
Cached Biology News:In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics 2In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics 3To drive infections, a hijacking virus mimics a cell's signaling system 2UC research: Saving habitat key to songbird's survival 2
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
... polyclonal to FbxL7 The F ... which it was originally observed, is ... binds SKP1. F-box proteins are components ... called SCFs (SKP1, cullin, F-box proteins), ...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Biology Products: